| 1 | Effect of agreement between clinician-rated and patient-reported PTSD symptoms on intensive outpatient treatment outcomes | 3.3 | 1 | Citations (PDF) |
| 2 | Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges | 2.6 | 10 | Citations (PDF) |
| 3 | Neuroanatomical dimensions in medication-free individuals with major depressive disorder and treatment response to SSRI antidepressant medications or placebo | 6.4 | 25 | Citations (PDF) |
| 4 | The utility of measuring daily hassles and uplifts in understanding outcomes to treatments for major depressive disorder | 3.3 | 4 | Citations (PDF) |
| 5 | The metabolome-wide signature of major depressive disorder | 8.5 | 23 | Citations (PDF) |
| 6 | A preliminary descriptive report of the longevity of the effects of Swedish Massage therapy for subjects with Generalized Anxiety Disorder | 1.2 | 2 | Citations (PDF) |
| 7 | Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators | 5.5 | 21 | Citations (PDF) |
| 8 | Functional connectivity of salience and affective networks among remitted depressed patients predicts episode recurrence | 5.5 | 13 | Citations (PDF) |
| 9 | Circulating metabolites modulated by diet are associated with depression | 8.5 | 41 | Citations (PDF) |
| 10 | Combinatorial pharmacogenomic algorithm is predictive of sertraline metabolism in patients with major depressive disorder | 3.3 | 10 | Citations (PDF) |
| 11 | The relations between C-reactive protein and trauma exposure, PTSD and depression symptoms, and PTSD psychotherapy treatment response in treatment seeking veterans and service members | 4.7 | 18 | Citations (PDF) |
| 12 | Metabolomic and inflammatory signatures of symptom dimensions in major depression | 4.7 | 88 | Citations (PDF) |
| 13 | A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults | 5.3 | 44 | Citations (PDF) |
| 14 | Genomics-based identification of a potential causal role for acylcarnitine metabolism in depression | 4.8 | 15 | Citations (PDF) |
| 15 | Rare copy number variation in posttraumatic stress disorder | 8.5 | 5 | Citations (PDF) |
| 16 | Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation | 2.8 | 54 | Citations (PDF) |
| 17 | Six versus twelve weeks of Swedish massage therapy for generalized anxiety disorder: Preliminary findings | 3.2 | 12 | Citations (PDF) |
| 18 | Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression | 1.2 | 1 | Citations (PDF) |
| 19 | Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation | 11.2 | 80 | Citations (PDF) |
| 20 | Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder | 1.9 | 9 | Citations (PDF) |
| 21 | Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression | 3.3 | 15 | Citations (PDF) |
| 22 | Combined effects of genotype and childhood adversity shape variability of DNA methylation across age | 5.5 | 37 | Citations (PDF) |
| 23 | Dry Those Crying Eyes | 1.9 | 20 | Citations (PDF) |
| 24 | Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression | 5.5 | 85 | Citations (PDF) |
| 25 | Safety of Using a Combinatorial Pharmacogenomic Test for Patients with Major Depressive Disorder in the GUIDED trial | 0.6 | 1 | Citations (PDF) |
| 26 | Establishing Evidence for Clinical Utility of a Neuroimaging Biomarker in Major Depressive Disorder: Prospective Testing and Implementation Challenges | 5.6 | 23 | Citations (PDF) |
| 27 | Moving on With Monoamine Oxidase Inhibitors | 1.2 | 8 | Citations (PDF) |
| 28 | An intensive outpatient program with prolonged exposure for veterans with posttraumatic stress disorder: Retention, predictors, and patterns of change. | 1.4 | 36 | Citations (PDF) |
| 29 | Indoxyl sulfate, a gut microbiome-derived uremic toxin, is associated with psychic anxiety and its functional magnetic resonance imaging-based neurologic signature | 3.5 | 87 | Citations (PDF) |
| 30 | Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression | 2.6 | 20 | Citations (PDF) |
| 31 | Psychophysiological treatment outcomes: Corticotropin‐releasing factor type 1 receptor antagonist increases inhibition of fear‐potentiated startle in PTSD patients | 2.6 | 26 | Citations (PDF) |
| 32 | Investigation of MORC1 DNA methylation as biomarker of early life stress and depressive symptoms | 3.0 | 12 | Citations (PDF) |
| 33 | Somatic symptoms in treatment‐naïve Hispanic and non‐Hispanic patients with major depression | 3.2 | 34 | Citations (PDF) |
| 34 | Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes | 4.8 | 52 | Citations (PDF) |
| 35 | ERICH3: vesicular association and antidepressant treatment response | 8.5 | 23 | Citations (PDF) |
| 36 | Combinatorial Pharmacogenomic Testing Improves Outcomes for Older Adults With Depression | 1.8 | 24 | Citations (PDF) |
| 37 | Concordance between clinician-rated and patient reported outcome measures of depressive symptoms in treatment resistant depression | 4.8 | 34 | Citations (PDF) |
| 38 | 150 HAM-D6 Outcomes in a Randomized, Controlled Trial Evaluating the Utility of Combinatorial Pharmacogenomics in Depression | 0.6 | 0 | Citations (PDF) |
| 39 | Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder | 3.3 | 29 | Citations (PDF) |
| 40 | Beyond the bins: interpreting and discussing pharmacogenomic reports with psychiatric patients | 1.1 | 2 | Citations (PDF) |
| 41 | Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder | 0.4 | 6 | Citations (PDF) |
| 42 | Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients | 5.5 | 76 | Citations (PDF) |
| 43 | Changes in trauma-potentiated startle, skin conductance, and heart rate within prolonged exposure therapy for PTSD in high and low treatment responders | 3.6 | 51 | Citations (PDF) |
| 44 | Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis | 3.6 | 51 | Citations (PDF) |
| 45 | Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment | 2.8 | 23 | Citations (PDF) |
| 46 | Recall accuracy for the symptoms of a major depressive episode among clinical trial participants | 3.0 | 15 | Citations (PDF) |
| 47 | 49 Combinatorial Pharmacogenomics to Guide Treatment Selection for Major Depressive Disorder: A Large, Blinded, Randomized Controlled Trial | 0.6 | 1 | Citations (PDF) |
| 48 | Moving pharmacoepigenetics tools for depression toward clinical use | 4.8 | 30 | Citations (PDF) |
| 49 | Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression | 10.5 | 60 | Citations (PDF) |
| 50 | Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial | 2.8 | 60 | Citations (PDF) |
| 51 | Comparing sensitivity to change using the 6-item versus the 17-item Hamilton depression rating scale in the GUIDED randomized controlled trial | 3.4 | 33 | Citations (PDF) |
| 52 | Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder | 4.2 | 20 | Citations (PDF) |
| 53 | Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study | 3.0 | 283 | Citations (PDF) |
| 54 | The hypothalamic-pituitary-adrenal axis in PTSD: Pathophysiology and treatment interventions | 4.0 | 203 | Citations (PDF) |
| 55 | Model structure for protocol adherence utilizing a manualized therapeutic massage intervention | 1.3 | 4 | Citations (PDF) |
| 56 | When translational neuroscience fails in the clinic: Dexamethasone prior to virtual reality exposure therapy increases drop-out rates | 3.6 | 46 | Citations (PDF) |
| 57 | Pharmacogenetic Tests and Depressive Symptom Remission: A Meta-Analysis of Randomized Controlled Trials | 1.7 | 168 | Citations (PDF) |
| 58 | Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder | 4.8 | 16 | Citations (PDF) |
| 59 | Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder | 1.9 | 18 | Citations (PDF) |
| 60 | Massage therapy decreases cancer‐related fatigue: Results from a randomized early phase trial | 4.1 | 68 | Citations (PDF) |
| 61 | Test–Retest Reliability of the SERT Imaging Agent <sup>11</sup>C-HOMADAM in Healthy Humans | 6.3 | 1 | Citations (PDF) |
| 62 | Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein | 10.5 | 46 | Citations (PDF) |
| 63 | Imaging the Future of Major Depression | 1.2 | 0 | Citations (PDF) |
| 64 | DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder | 4.1 | 42 | Citations (PDF) |
| 65 | Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse | 3.2 | 36 | Citations (PDF) |
| 66 | Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools | 2.8 | 100 | Citations (PDF) |
| 67 | Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders | 4.8 | 40 | Citations (PDF) |
| 68 | Performance of the Adult ADHD Self-Report Scale-v1.1 in Adults with Major Depressive Disorder | 2.3 | 34 | Citations (PDF) |
| 69 | Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response | 12.4 | 212 | Citations (PDF) |
| 70 | Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults | 2.3 | 14 | Citations (PDF) |
| 71 | Follow-up of monotherapy remitters in the PReDICT study: Maintenance treatment outcomes and clinical predictors of recurrence. | 2.4 | 16 | Citations (PDF) |
| 72 | The structure of personality disorders within a depressed sample: Implications for personalizing treatment | 0.4 | 3 | Citations (PDF) |
| 73 | D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders | 13.3 | 275 | Citations (PDF) |
| 74 | Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study | 10.5 | 132 | Citations (PDF) |
| 75 | Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder | 10.5 | 324 | Citations (PDF) |
| 76 | Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression | 3.2 | 35 | Citations (PDF) |
| 77 | Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder | 5.6 | 88 | Citations (PDF) |
| 78 | Reported maladaptive decision-making in unipolar and bipolar depression and its change with treatment | 3.3 | 19 | Citations (PDF) |
| 79 | Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings | 2.3 | 57 | Citations (PDF) |
| 80 | Surveying Psychiatrists’ Psychopharmacology Practices Across Common Clinical Scenarios | 1.2 | 1 | Citations (PDF) |
| 81 | Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA) | 2.9 | 92 | Citations (PDF) |
| 82 | Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity | 4.9 | 35 | Citations (PDF) |
| 83 | Pharmacogenetic Decision Support Tools: A Component of Precision Medicine for Psychiatry? | 1.2 | 1 | Citations (PDF) |
| 84 | Evidence-Based Applications of Combination Psychotherapy and Pharmacotherapy for Depression | 1.2 | 32 | Citations (PDF) |
| 85 | Time-dependent effects of dexamethasone plasma concentrations on glucocorticoid receptor challenge tests | 2.8 | 36 | Citations (PDF) |
| 86 | Divergent Outcomes in Cognitive-Behavioral Therapy and Pharmacotherapy for Adult Depression | 10.5 | 49 | Citations (PDF) |
| 87 | When Should a Patient Be Declared Recovered From a Major Depressive Episode? | 2.8 | 5 | Citations (PDF) |
| 88 | Acute Swedish Massage Monotherapy Successfully Remediates Symptoms of Generalized Anxiety Disorder | 2.8 | 36 | Citations (PDF) |
| 89 | Mediators of Sexual Functioning and Marital Quality in Chronically Depressed Adults with and Without a History of Childhood Sexual Abuse | 0.5 | 34 | Citations (PDF) |
| 90 | Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression | 2.3 | 40 | Citations (PDF) |
| 91 | Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy | 13.3 | 178 | Citations (PDF) |
| 92 | The Over-Under on the Misdiagnosis of Bipolar Disorder: A Systematic Review | 0.4 | 3 | Citations (PDF) |
| 93 | Antidepressant Signal Detection in the Clinical Trials Vortex | 2.8 | 4 | Citations (PDF) |
| 94 | Use of Dialectical Behavior Therapy in Borderline Personality Disorder: A View From Residency | 0.6 | 8 | Citations (PDF) |
| 95 | A Randomized, Double-Blind Evaluation of <scp>d</scp>-Cycloserine or Alprazolam Combined With Virtual Reality Exposure Therapy for Posttraumatic Stress Disorder in Iraq and Afghanistan War Veterans | 10.5 | 391 | Citations (PDF) |
| 96 | GENDER AS PREDICTOR AND MODERATOR OF OUTCOME IN COGNITIVE BEHAVIOR THERAPY AND PHARMACOTHERAPY FOR ADULT DEPRESSION: AN “INDIVIDUAL PATIENT DATA” META-ANALYSIS | 3.2 | 149 | Citations (PDF) |
| 97 | Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP) | 2.3 | 47 | Citations (PDF) |
| 98 | How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine | 1.8 | 12 | Citations (PDF) |
| 99 | ENHANCING HISPANIC PARTICIPATION IN MENTAL HEALTH CLINICAL RESEARCH: DEVELOPMENT OF A SPANISH-SPEAKING DEPRESSION RESEARCH SITE | 3.2 | 29 | Citations (PDF) |
| 100 | Ziprasidone monotherapy is ineffective for bipolar-associated anxiety | 8.6 | 0 | Citations (PDF) |
| 101 | Combination Psychotherapy and Antidepressant Medication Treatment for Depression: For Whom, When, and How | 23.4 | 88 | Citations (PDF) |
| 102 | Corrigendum to “Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder” [J Psychiatr Res 46 (2012) 375–381] | 3.0 | 2 | Citations (PDF) |
| 103 | REVIEW OF NUTRITIONAL SUPPLEMENTS FOR THE TREATMENT OF BIPOLAR DEPRESSION | 3.2 | 18 | Citations (PDF) |
| 104 | Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: Examining the convergence of performance-based measures and self-reports | 3.0 | 38 | Citations (PDF) |
| 105 | Pretreatment Brain States Identify Likely Nonresponse to Standard Treatments for Depression | 5.6 | 129 | Citations (PDF) |
| 106 | MicroRNA 135 Is Essential for Chronic Stress Resiliency, Antidepressant Efficacy, and Intact Serotonergic Activity | 12.4 | 356 | Citations (PDF) |
| 107 | Cognitive Effects of Quetiapine XR in Patients With Euthymic Bipolar Disorder | 1.9 | 7 | Citations (PDF) |
| 108 | Neuroimaging-based biomarkers for treatment selection in major depressive disorder | 5.6 | 119 | Citations (PDF) |
| 109 | Do alcohol use disorders destabilize the course of bipolar disorder? | 4.8 | 46 | Citations (PDF) |
| 110 | Toward a Neuroimaging Treatment Selection Biomarker for Major Depressive Disorder | 13.3 | 522 | Citations (PDF) |
| 111 | Posttraumatic Stress Disorder Increases Sensitivity to Long Term Losses among Patients with Major Depressive Disorder | 2.4 | 35 | Citations (PDF) |
| 112 | Reconciling Variable Findings of White Matter Integrity in Major Depressive Disorder | 5.5 | 62 | Citations (PDF) |
| 113 | Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder | 2.8 | 84 | Citations (PDF) |
| 114 | US Psychiatric Residents’ Treatment of Patients With Bipolar Disorder | 1.9 | 14 | Citations (PDF) |
| 115 | A Meta-analysis of Factors Impacting Detection of Antidepressant Efficacy in Clinical Trials: The Importance of Academic Sites | 5.5 | 66 | Citations (PDF) |
| 116 | The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder | 3.0 | 189 | Citations (PDF) |
| 117 | Depression beliefs, treatment preference, and outcomes in a randomized trial for major depressive disorder | 3.0 | 72 | Citations (PDF) |
| 118 | Recovery and subsequent recurrence in patients with recurrent major depressive disorder | 3.0 | 14 | Citations (PDF) |
| 119 | Preconsent education about research processes improved African Americans’ willingness to participate in clinical research | 3.8 | 31 | Citations (PDF) |
| 120 | The effects of sertraline on psychopathic traits | 1.4 | 22 | Citations (PDF) |
| 121 | Symptomatic and Functional Improvement in Employed Depressed Patients | 1.9 | 75 | Citations (PDF) |
| 122 | Conceptualizing Treatment Nonadherence in Patients with Bipolar Disorder and PTSD | 0.6 | 18 | Citations (PDF) |
| 123 | Will current socioeconomic trends produce a depressing future
for men? | 2.0 | 13 | Citations (PDF) |
| 124 | Tolerability of the dexamethasone–corticotropin releasing hormone test in major depressive disorder | 3.0 | 5 | Citations (PDF) |
| 125 | Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder | 3.0 | 52 | Citations (PDF) |
| 126 | Public Health Consequences of State Immigration Laws | 0.5 | 9 | Citations (PDF) |
| 127 | Treating Nonspecific Anxiety and Anxiety Disorders in Patients With Bipolar Disorder | 2.8 | 47 | Citations (PDF) |
| 128 | An Additional Consideration for Comparisons of Antidepressants Versus Placebo | 1.9 | 1 | Citations (PDF) |
| 129 | Response to Treatment with Placebo, Medication or Psychotherapy in Severe Non- Psychotic Major Depressive Disorder | 0.4 | 5 | Citations (PDF) |
| 130 | Test–retest reliability of the SERT imaging agent [11C]HOMADAM in healthy humans | 4.5 | 0 | Citations (PDF) |
| 131 | Correlation between patient and clinician assessments of depression severity in the PREVENT study | 3.3 | 48 | Citations (PDF) |
| 132 | Exploratory structural equation modeling of resting-state fMRI: Applicability of group models to individual subjects | 4.5 | 67 | Citations (PDF) |
| 133 | Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population | 1.4 | 29 | Citations (PDF) |
| 134 | Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75–225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study | 1.4 | 15 | Citations (PDF) |
| 135 | Combination Treatment With Benzodiazepines and SSRIs for Comorbid Anxiety and Depression | 0.9 | 91 | Citations (PDF) |
| 136 | Coadministration of Modafinil and a Selective Serotonin Reuptake Inhibitor From the Initiation of Treatment of Major Depressive Disorder With Fatigue and Sleepiness | 1.9 | 51 | Citations (PDF) |
| 137 | The Impact of HIPAA Authorization on Willingness to Participate in Clinical Research | 1.8 | 29 | Citations (PDF) |
| 138 | The Role of Dopamine in the Pathophysiology of Depression | 13.8 | 1,129 | Citations (PDF) |
| 139 | The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases | 5.6 | 40 | Citations (PDF) |
| 140 | Tiagabine for social anxiety disorder | 1.8 | 35 | Citations (PDF) |
| 141 | Commentary | 0.6 | 1 | Citations (PDF) |
| 142 | Assessment of human exposure and human health effects after indoor application of methyl parathion in Lorain County, Ohio, 1995-1996. | 8.8 | 35 | Citations (PDF) |
